Join the club for FREE to access the whole archive and other member benefits.

Elysium Health releases new studies on its Basis NR supplement


Key points from article :

Previously shown that Basis safely and sustainably increases NAD+ levels by an average of 40%.

Elysium’s NAD+ baseline study is ongoing.

Elysium recently shared the results of two studies for Basis.

1. acute kidney injury (AKI) Phase I dose-escalating safety study conducted at Massachusetts General Hospital

Gained its first Investigational New Drug (IND) application from the FDA late last year.

Made possible by Elysium’s open-access research model

2. 90-day toxicity study

Demonstrates the superior safety of Elysium’s proprietary nicotinamide riboside (NR-E)

Nicotinamide riboside is a precursor to NAD+ and classifies as GRAS (generally recognized as safe).

Demonstrates safety as a NAD+ precursor dietary supplement, and also within a drug clinical trial

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


A company focused on research and development based on new scientific findings

Health Organisation

Largest teaching hospital of Harvard Medical School located in Boston